SAM
DRNA

Silphium Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Silphium Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,531
Closed -$191K – 107
2018
Q3 		$191K Sell
12,531
-1,300
-9% -$18.9K 0.05% 119
2018
Q2 		$169K Sell
13,831
-16,394
-54% -$206K 0.05% 100
2018
Q1 		$289K Buy
+30,225
New +$326K 0.16% 57

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Silphium Asset Management's DRNA Position: Q4 2018 in Review

Silphium Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2018, closing a stake of 12,531 shares — an estimated $191K sold.

Silphium Asset Management first reported a position in DRNA in Q1 2018 and held it in 3 quarters. The position peaked at $289K in Q1 2018. 103 funds tracked by Wall St. Rank hold DRNA as of Q4 2018.

  • Silphium Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Silphium Asset Management sold 12,531 Dicerna Pharmaceuticals, Inc. shares in Q4 2018, an estimated $191K.
  • Silphium Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
  • Silphium Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $289K in Q1 2018.
  • 103 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2018.

Based on Silphium Asset Management's 13F filing for Q4 2018, filed 30 Jan 2025.